HK1201750A1 - 使用 激酶抑制劑的癌症治療 - Google Patents
使用 激酶抑制劑的癌症治療Info
- Publication number
- HK1201750A1 HK1201750A1 HK15102376.3A HK15102376A HK1201750A1 HK 1201750 A1 HK1201750 A1 HK 1201750A1 HK 15102376 A HK15102376 A HK 15102376A HK 1201750 A1 HK1201750 A1 HK 1201750A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- tor
- cancer
- treatment
- kinase inhibitors
- tor kinase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261611361P | 2012-03-15 | 2012-03-15 | |
US201261715323P | 2012-10-18 | 2012-10-18 | |
PCT/US2013/031206 WO2013138557A1 (en) | 2012-03-15 | 2013-03-14 | Treatment of cancer with tor kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1201750A1 true HK1201750A1 (zh) | 2015-09-11 |
Family
ID=48014336
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15102376.3A HK1201750A1 (zh) | 2012-03-15 | 2015-03-09 | 使用 激酶抑制劑的癌症治療 |
Country Status (22)
Country | Link |
---|---|
US (1) | US20130245026A1 (zh) |
EP (1) | EP2825170B1 (zh) |
JP (3) | JP2015510891A (zh) |
KR (3) | KR20210071101A (zh) |
CN (2) | CN104519885A (zh) |
AU (1) | AU2013203153B2 (zh) |
BR (1) | BR112014022703A2 (zh) |
CA (1) | CA2866872A1 (zh) |
EA (1) | EA028414B1 (zh) |
ES (1) | ES2677874T3 (zh) |
HK (1) | HK1201750A1 (zh) |
IL (1) | IL234602B (zh) |
MX (1) | MX360878B (zh) |
MY (1) | MY174022A (zh) |
NI (1) | NI201400111A (zh) |
NZ (1) | NZ628416A (zh) |
PH (1) | PH12014502029A1 (zh) |
SG (1) | SG11201405707XA (zh) |
TW (1) | TWI583385B (zh) |
UA (1) | UA114315C2 (zh) |
WO (1) | WO2013138557A1 (zh) |
ZA (1) | ZA201406706B (zh) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210071101A (ko) * | 2012-03-15 | 2021-06-15 | 시그날 파마소티칼 엘엘씨 | Tor 키나제 억제자를 사용하는 암의 치료 |
AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
TW201441227A (zh) | 2013-01-16 | 2014-11-01 | Signal Pharm Llc | 經取代吡咯并嘧啶化合物、其組合物及其治療方法 |
WO2014172425A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
US9358232B2 (en) | 2013-04-17 | 2016-06-07 | Signal Pharmaceuticals, Llc | Methods for treating cancer using TOR kinase inhibitor combination therapy |
BR112015026247B1 (pt) | 2013-04-17 | 2022-08-23 | Signal Pharmaceuticals, Llc | Uso de compostos em combinação com um análogo de citidina, composição farmacêutica que os compreende, e kit |
WO2014172424A1 (en) * | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
EP2986298A1 (en) | 2013-04-17 | 2016-02-24 | Signal Pharmaceuticals, LLC | Treatment of cancer with dihydropyrazino-pyrazines |
CA2909625C (en) | 2013-04-17 | 2021-06-01 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer |
SG11201508527VA (en) | 2013-04-17 | 2015-11-27 | Signal Pharm Llc | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one |
BR112015026257B1 (pt) | 2013-04-17 | 2022-12-20 | Signal Pharmaceuticals, Llc | Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit |
CN113831345A (zh) | 2013-05-29 | 2021-12-24 | 西格诺药品有限公司 | 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途 |
WO2015160880A1 (en) | 2014-04-16 | 2015-10-22 | Signal Pharmaceuticals, Llc | SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
EP3131552B1 (en) | 2014-04-16 | 2020-07-15 | Signal Pharmaceuticals, LLC | Methods for treating cancer using tor kinase inhibitor combination therapy |
NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
NZ629796A (en) | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
EA201790189A1 (ru) | 2014-07-14 | 2017-11-30 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Способы лечения злокачественного новообразования с использованием замещенных пирролопиримидиновых соединений, композиции на их основе |
AU2018289539B2 (en) | 2017-06-22 | 2024-07-04 | Celgene Corporation | Treatment of hepatocellular carcinoma characterized by hepatitis B virus infection |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2627352T3 (es) | 2006-10-19 | 2017-07-27 | Signal Pharmaceuticals, Llc | Compuestos heteroarilo, sus composiciones y su uso como inhibidores de proteínas quinasas |
WO2008051494A1 (en) | 2006-10-19 | 2008-05-02 | Signal Pharmaceuticals, Llc | Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors |
WO2010022243A1 (en) * | 2008-08-20 | 2010-02-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chemoprevention of head and neck squamous cell carcinomas |
US8110578B2 (en) * | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
BR112012009751A2 (pt) | 2009-10-26 | 2020-09-24 | Signal Pharmaceuticals, Llc | métodos de síntese e purificação de heteroarila |
US20120028972A1 (en) * | 2010-07-30 | 2012-02-02 | Lilly Wong | Biomarker assays for detecting or measuring inhibition of tor kinase activity |
KR20210071101A (ko) * | 2012-03-15 | 2021-06-15 | 시그날 파마소티칼 엘엘씨 | Tor 키나제 억제자를 사용하는 암의 치료 |
-
2013
- 2013-03-14 KR KR1020217017407A patent/KR20210071101A/ko not_active Application Discontinuation
- 2013-03-14 MX MX2014011077A patent/MX360878B/es active IP Right Grant
- 2013-03-14 US US13/803,061 patent/US20130245026A1/en not_active Abandoned
- 2013-03-14 TW TW102109160A patent/TWI583385B/zh active
- 2013-03-14 UA UAA201411218A patent/UA114315C2/uk unknown
- 2013-03-14 BR BR112014022703-9A patent/BR112014022703A2/pt not_active IP Right Cessation
- 2013-03-14 EA EA201491699A patent/EA028414B1/ru not_active IP Right Cessation
- 2013-03-14 AU AU2013203153A patent/AU2013203153B2/en not_active Ceased
- 2013-03-14 KR KR1020147028707A patent/KR102122617B1/ko active IP Right Grant
- 2013-03-14 NZ NZ628416A patent/NZ628416A/en not_active IP Right Cessation
- 2013-03-14 CN CN201380024859.XA patent/CN104519885A/zh active Pending
- 2013-03-14 JP JP2015500596A patent/JP2015510891A/ja active Pending
- 2013-03-14 CA CA2866872A patent/CA2866872A1/en not_active Abandoned
- 2013-03-14 ES ES13713006.8T patent/ES2677874T3/es active Active
- 2013-03-14 EP EP13713006.8A patent/EP2825170B1/en active Active
- 2013-03-14 WO PCT/US2013/031206 patent/WO2013138557A1/en active Application Filing
- 2013-03-14 SG SG11201405707XA patent/SG11201405707XA/en unknown
- 2013-03-14 CN CN201811057528.7A patent/CN108992446A/zh active Pending
- 2013-03-14 KR KR1020207016306A patent/KR20200070416A/ko not_active IP Right Cessation
- 2013-03-14 MY MYPI2014702568A patent/MY174022A/en unknown
-
2014
- 2014-09-11 IL IL234602A patent/IL234602B/en active IP Right Grant
- 2014-09-12 NI NI201400111A patent/NI201400111A/es unknown
- 2014-09-12 ZA ZA2014/06706A patent/ZA201406706B/en unknown
- 2014-09-12 PH PH12014502029A patent/PH12014502029A1/en unknown
-
2015
- 2015-03-09 HK HK15102376.3A patent/HK1201750A1/zh unknown
-
2019
- 2019-03-04 JP JP2019038434A patent/JP2019108368A/ja active Pending
-
2021
- 2021-03-24 JP JP2021050188A patent/JP2021102637A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL274318A (en) | Cancer treatment with rapamycin target site kinase inhibitors | |
HK1243919A1 (zh) | 利用tor激酶抑制劑治療癌症 | |
HK1202247A1 (zh) | 激酶抑制劑治療癌症 | |
HK1201750A1 (zh) | 使用 激酶抑制劑的癌症治療 | |
HK1220640A1 (zh) | 用谷氨醯胺酶的雜環抑制劑治療癌症 | |
HK1201753A1 (zh) | 使用 激酶抑制劑的癌症治療 | |
ZA201503105B (en) | Treatment of prostate cancer with tor kinase inhibitors | |
EP2903644A4 (en) | TREATMENT OF CANCER | |
GB201217892D0 (en) | Treatment of cancer | |
HK1204956A1 (zh) | 癌症治療 | |
HK1205500A1 (zh) | 用於癌症治療的激酶抑制劑 | |
EP2897607A4 (en) | BETA-HYDROLASE INHIBITORS FOR THE TREATMENT OF CANCER | |
GB201217890D0 (en) | Treatment of cancer | |
ZA201502294B (en) | Treatment of cancer with tor kinase inhibitors | |
GB201208296D0 (en) | Treatment of cancer |